| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10596400 | Bioorganic & Medicinal Chemistry Letters | 2009 | 6 Pages |
Abstract
Strategies aiming at reducing hERG-associated liabilities in a class of potent MCH-R1 antagonists are presented.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Susanne Berglund, Bryan J. Egner, Henrik Gradén, Joakim Gradén, David G.A. Morgan, Tord Inghardt, Fabrizio Giordanetto,